DXN HOLDINGS BHD.
KLSE (MYR): DXN (5318)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.575
Today's Change
+0.005 (0.88%)
Day's Change
0.575 - 0.575
Trading Volume
154,500
Company warrants are issued by the company and give the holders the right, but not an obligation, to subscribe for new ordinary shares at a specified price during a specified period of time.
Structured warrants are proprietary instruments issued by a third-party issuer, namely an eligible broker or financial institution that give holders the right, but not the obligation, to buy (call warrants) or sell (put warrant) the underlying instrument in the future for a fixed price.
A call warrant is in-the-money when the exercise price is lower than the price of the underlying share.
A put warrant is in-the-money when the underlying share price is lower than the exercise price.
Call Warrants
In the money
Discussions
Be the first to like this. Showing 50 of 459 comments
Buy, dividend ~6%
DXN Holdings 1Q net profit up 10.26%, targets market presence in Zambia, Ghana
2 months ago
Post-briefing update
Sales momentum in the majority of DXN’s operating regions have performed well in 1QFY25 but the surge in DXN’s core raw material costs will eventually weigh on group margins as product price adjustments may not fully offset higher production costs. We lower our FY25E-FY27E earnings estimate by 5%-8%. Rolling forward valuations to CY25E, our TP is lowered to MYR0.85 based on an unchanged 11x PER. Maintain BUY.
2 months ago
DXN Holdings Berhad is a Malaysian company that primarily operates in the health and wellness sector. It is known for its production of dietary supplements, food and beverages, personal care products, and household items, with a focus on Ganoderma-based products.
In terms of potential, DXN Holdings has several factors in its favor:
1. **Global Reach**: DXN operates in over 180 countries with a large network of independent distributors. This wide global footprint provides a strong base for growth, especially in emerging markets where health and wellness trends are increasing.
2. **Growing Health and Wellness Market**: The global demand for supplements, particularly those promoting natural health benefits, is on the rise. DXN's core product offerings align with consumer trends favoring organic and herbal supplements.
3. **Multi-level Marketing Model**: DXN uses a direct selling approach through a multi-level marketing (MLM) model. While MLM has risks and is highly regulated, DXN has sustained a large base of distributors, which supports consistent revenue generation.
4. **Product Diversification**: Beyond supplements, DXN has diversified into other product categories like food, beverages, cosmetics, and personal care. This reduces reliance on any single product and opens opportunities in various sectors.
5. **Sustainability Focus**: DXN’s focus on natural and organic products positions it well in markets that value sustainability and eco-friendly consumption.
Overall, DXN’s strong brand, global presence, and product diversification offer significant growth potential, particularly if it capitalizes on the increasing demand for wellness products.
1 month ago
DXN Holdings Berhad was founded by **Datuk Dr. Lim Siow Jin** in 1993. He is a renowned figure in the wellness industry, especially for his pioneering work with **Ganoderma**, a type of mushroom that is believed to have various health benefits. Dr. Lim's background in holistic health and his passion for natural remedies drove him to establish DXN, focusing on products that promote overall wellness.
Dr. Lim is also well-regarded for his vision of combining the principles of traditional medicine with modern scientific research, particularly in the cultivation and commercialization of Ganoderma. Under his leadership, DXN has grown into a global network, with a presence in over 180 countries, making it one of the prominent names in the direct-selling wellness industry.
His leadership and vision continue to play a significant role in DXN's success and global expansion.
1 month ago
Datuk Dr. Lim Siow Jin, the founder of DXN Holdings, holds a degree in **Engineering** from the **Indian Institute of Technology (IIT), Bombay**. Despite his engineering background, he became deeply interested in traditional medicine, particularly in the health benefits of **Ganoderma** (also known as Lingzhi or Reishi mushrooms), which led him to establish DXN.
Dr. Lim also pursued further studies and research in holistic health and traditional herbal medicine, which played a crucial role in the development of DXN's products. His scientific approach, combined with a passion for natural wellness, has been a key factor in DXN's success in promoting Ganoderma-based health solutions globally.
1 month ago
DXN, a Malaysian-based company, is a global network marketing (MLM) enterprise primarily known for its cultivation, manufacture, and distribution of health and wellness products. Here are some key reasons why DXN might be of interest:
1. **Ganoderma Expertise**: DXN is renowned for its use of **Ganoderma** (a type of mushroom known for its medicinal properties) in its health products. It’s a pioneer in cultivating and marketing this product, which is central to their offerings, particularly in supplements, teas, coffees, and skincare.
2. **Global Reach**: DXN operates in over 180 countries and has a large distributor base. Its global footprint has made it one of the largest MLM companies in Asia, and it has expanded rapidly in regions like Latin America, Africa, and the Middle East.
3. **Network Marketing Model**: As an MLM company, DXN provides opportunities for people to become distributors and earn income through sales and recruitment. This business model has attracted a wide range of individuals looking for entrepreneurial opportunities, especially in developing countries.
4. **Health and Wellness Focus**: DXN’s products cater to the growing global trend of health-conscious consumers, focusing on herbal-based supplements, organic products, and natural remedies. This sector has seen a steady rise, making DXN's offerings more relevant.
5. **Vertical Integration**: DXN controls the entire production process, from farming to manufacturing to distribution. This vertical integration ensures product quality and gives the company better control over costs and supply chains.
6. **Stock Market Listing**: DXN went public and is listed on the Malaysian stock exchange (Bursa Malaysia). It is a point of interest for investors due to its global reach and profitability.
7. **Sustainability & Agriculture**: DXN has been involved in sustainable agricultural practices, especially in the cultivation of Ganoderma, and they emphasize organic farming in their production process.
8. **Resilience in the Market**: The company has maintained steady growth even during challenging economic periods due to its global reach, diverse product range, and growing health-conscious customer base.
These factors contribute to why DXN is often discussed in business, wellness, and investment circles.
1 month ago
Last Price
0.615
Avg Target Price
0.89
Upside/Downside
+0.275 (44.72%)
https://klse.i3investor.com/web/stock/analysis-price-target/5318
1 month ago
very low-profile money-making company, will steady dividend worth while to invest.
1 month ago
just grab from contra players hehe... buy cheaply from margin players... once in a lifetime yah hehe
1 month ago
Direct deal
History
Date Price Change Dir-Volume Day Volume Dir-Value Day Value Avg Price % of Total Share Remarks
15/01/2024 00:00:00 0.6900 -0.0050 36.200m 36.200m 24.978m 24.978m 0.6900 0.7262 -
09/01/2024 00:00:00 0.6950 -0.0050 35.900m 35.900m 24.951m 24.951m 0.6950 0.7202 -
07/08/2023 00:00:00 0.7000 -0.0250 65,790 65,790 46,053 46,053 0.7000 0.0013 -
23/06/2023 00:00:00 0.7000 0.0400 1.000m 1.000m 700,000 700,000 0.7000 0.0201 -
19/05/2023 00:00:00 0.7350 0.0350 1.500m 1.500m 1.103m 1.103m 0.7350 0.0301 -
Summary from 19/05/2023 to 15/01/2024
Highest Price 0.7350 First Occurred on 19/05/2023
Lowest Price 0.6900 First Occurred on 15/01/2024
Highest Volume 36.200m First Occurred on 15/01/2024
1 month ago
DXN did very well in:
Broadening the Products/Markets The future survival and success of a Company hinges on its products and markets.
Under today's highly competitive business environment, there is no guarantee that a
company possessing a very successful product in a very lucrative market will continue to
enjoy such success. Competitors will always try to introduce competing or alternative
products with enhanced performance at greatly reduced price (products and market
strategy). To broaden the product/market base. For example, several successful products
operating in many markets is actually building a strong defence invulnerable to attack.
Building Up Resilience to Recessionary Conditions To build up its resilience against the recessionary pressure. For example, a Company with
a proactive management can expect and sense the approaching of a recession, and work
out strategies in terms of its product/market mix well in advance to reduce the adverse
impact of recession. Moreover, the management may also take some precautionary
measures to make the Company lean, in a stronger position to face the downturn.
1 month ago
All in...
Maybank's target price for DXN Holdings Berhad at 85 sen likely reflects an in-depth analysis of the company's financials, market position, and industry trends. Let’s dive into the exciting details behind this target price!
### **1. **Financial Performance:**
- **Revenue and Profit Growth**: DXN’s recent financial reports might show robust revenue and profit growth, especially in the direct selling industry. Analysts like Maybank would closely evaluate these figures to project future earnings.
- **Earnings Per Share (EPS)**: A strong EPS growth trend could be a key factor in setting the target price. If DXN is delivering impressive EPS figures, it would positively influence Maybank’s valuation.
### **2. **Market Position and Competitive Advantage:**
- **Strong Brand Presence**: DXN, known for its direct selling of health and wellness products, has established a strong brand presence. This competitive advantage can lead to higher market share and better financial performance.
- **Product Line and Innovation**: The company’s diverse and innovative product line, including its flagship Ganoderma-based products, could be contributing to its growth. If DXN is seen as a leader in product innovation, it enhances its investment appeal.
### **3. **Industry Trends:**
- **Growth in Health & Wellness**: The health and wellness industry is experiencing significant growth. If DXN is well-positioned to capitalize on this trend, it could drive higher revenues and profits.
- **Direct Selling Dynamics**: The direct selling model can be highly profitable with lower overhead costs. Analysts might view DXN’s efficiency in this model as a positive factor for future performance.
### **4. **Valuation Metrics:**
- **Discounted Cash Flow (DCF) Analysis**: Maybank might use DCF analysis to estimate the present value of DXN’s future cash flows. A target price of 85 sen could be derived from this valuation method, reflecting the company’s potential to generate future cash flow.
- **Price-to-Earnings (P/E) Ratio**: Comparing DXN’s P/E ratio with industry peers might show it is undervalued or fairly valued at 85 sen. This metric helps analysts gauge whether the stock price aligns with earnings expectations.
### **5. **Market Sentiment and External Factors:**
- **Regulatory Environment**: Positive or stable regulatory conditions for direct selling companies in Malaysia can support a higher target price.
- **Economic Conditions**: Favorable economic conditions and consumer spending trends in Malaysia and other markets where DXN operates could boost its stock price expectations.
### **6. **Strategic Initiatives and Expansion Plans:**
- **New Markets and Products**: DXN’s plans to enter new markets or launch new products can create excitement about its growth prospects. If Maybank sees these initiatives as promising, it could positively impact the target price.
- **Partnerships and Alliances**: Strategic partnerships or alliances that enhance DXN’s market position could be factored into the target price.
### **Excitement Behind the Target Price!**
Imagine DXN as a dynamic company riding the wave of booming health and wellness trends. With a solid financial performance, a winning direct selling model, and exciting product innovations, DXN is like a rocket on the launch pad, ready to soar to new heights. Maybank’s target price of 85 sen reflects their confidence in DXN’s potential to achieve great things and deliver solid returns for investors!
So, if you’re watching DXN, think of it as a thrilling opportunity in a high-growth sector, with plenty of excitement on the horizon! 🚀📈
1 month ago
buy more
DATUK LIM SIOW JIN 09-Jan-2024 Others 80,000,000 0.625
DATUK LIM SIOW JIN 30-Nov-2023 Acquired 345,000 0.651
DATUK LIM SIOW JIN 29-Nov-2023 Acquired 219,600 0.660
DATUK LIM SIOW JIN 28-Nov-2023 Acquired 132,100 0.666
DATUK LIM SIOW JIN 27-Nov-2023 Acquired 98,000 0.663
DATUK LIM SIOW JIN 24-Nov-2023 Acquired 292,300 0.668
DATUK LIM SIOW JIN 23-Nov-2023 Acquired 91,000 0.672
DATUK LIM SIOW JIN 22-Nov-2023 Acquired 133,600 0.659
DATUK LIM SIOW JIN 22-Sep-2023 Acquired 769,100 0.689
DATUK LIM SIOW JIN 21-Sep-2023 Acquired 169,700 0.690
DATUK LIM SIOW JIN 18-Sep-2023 Acquired 115,000 0.699
DATUK LIM SIOW JIN 15-Sep-2023 Acquired 190,600 0.700
DATUK LIM SIOW JIN 14-Sep-2023 Acquired 90,000 0.704
DATUK LIM SIOW JIN 13-Sep-2023 Acquired 684,600 0.699
DATUK LIM SIOW JIN 12-Sep-2023 Acquired 1,863,900 0.694
DATUK LIM SIOW JIN 11-Sep-2023 Acquired 60,000 0.685
MISS ONG HUEY MIN 07-Sep-2023 Acquired 20,000 0.705
MISS ONG HUEY MIN 06-Sep-2023 Acquired 25,000 0.700
MISS ONG HUEY MIN 05-Sep-2023 Acquired 25,000 0.695
MISS ONG HUEY MIN 30-May-2023 Acquired 20,000 0.650
MISS ONG HUEY MIN 29-May-2023 Acquired 10,000 0.655
MISS ONG HUEY MIN 26-May-2023 Acquired 20,000 0.645
MR TEOH HANG CHING 18-May-2023 Others 830,000 0.700
MR TEOH HANG CHING 18-May-2023 Others 39,000 0.700
MR TEOH HANG CHING 18-May-2023 Others 36,000
1 month ago
share buyback, anytime? hehe
From To Type No. of Shares Min Price Max Price
28-Feb-2024 28-Feb-2024 Buyback 1,694,100 0.630 0.630
27-Feb-2024 27-Feb-2024 Buyback 2,242,600 0.630 0.630
26-Feb-2024 26-Feb-2024 Buyback 4,437,800 0.630 0.635
23-Feb-2024 23-Feb-2024 Buyback 1,660,000 0.635 0.640
22-Feb-2024 22-Feb-2024 Buyback 746,800 0.640 0.640
22-Feb-2024 28-Feb-2024 Buyback 10,781,300 0.630 0.640
02-Nov-2023 02-Nov-2023 Buyback 30,000 0.665 0.675
01-Nov-2023 01-Nov-2023 Buyback 200,000 0.660 0.665
31-Oct-2023 31-Oct-2023 Buyback 189,000 0.655 0.675
30-Oct-2023 30-Oct-2023 Buyback 670,200 0.660 0.680
27-Oct-2023 27-Oct-2023 Buyback 190,000 0.670 0.685
26-Oct-2023 26-Oct-2023 Buyback 178,000 0.660 0.675
26-Oct-2023 02-Nov-2023 Buyback 1,457,200 0.655 0.685
1 month ago
DXN's shares appear to be undervalued for several reasons. First, its reliance on the multi-level marketing (MLM) model, while profitable, carries a higher level of regulatory risk and market perception challenges. MLMs are often viewed with skepticism, which can deter some investors from the stock. Additionally, despite its global presence and product diversification in wellness and organic products, the company may face pricing pressure and competition in the rapidly evolving health industry.
The stock's performance also reflects the broader sentiment towards companies like DXN that cater to niche health markets. Although the company is profitable, the share price does not yet reflect its full potential, perhaps due to market apprehension about its MLM structure and concerns regarding growth scalability. Moreover, as of recent data, the stock was trading at 0.615, well below the target price of 0.89, indicating a potential upside of over 44%, suggesting the stock might be undervalued by the market.
1 month ago
History tends to repeat itself 😃
DXN Holdings Bhd (KL:DXN) is set to see an uptrend reversal after bouncing off the 21-day simple moving average line and testing the 66 sen immediate resistance level on Tuesday.
In a trading stocks note on Wednesday, the research house said that if a breakout occurs above this level, bullish momentum may propel the stock towards the 72 sen resistance, and then towards the next resistance level at 77 sen.
1 month ago
Post-briefing update
Sales momentum in the majority of DXN’s operating regions have performed well in 1QFY25 but the surge in DXN’s core raw material costs will eventually weigh on group margins as product price adjustments may not fully offset higher production costs. We lower our FY25E-FY27E earnings estimate by 5%-8%. Rolling forward valuations to CY25E, our TP is lowered to MYR0.85 based on an unchanged 11x PER. Maintain BUY
Source: Maybank
1 month ago
DXN Holdings Bhd (DXN) is a Malaysian-based company primarily involved in the production and distribution of health and wellness products, particularly those centered around Ganoderma lucidum (reishi mushroom). Here are several reasons why DXN is often considered to have unlimited potential:
1. Growing Health and Wellness Industry
• Rising Demand: The global health and wellness market is expanding as consumers increasingly prioritize health, nutrition, and preventive care. DXN’s product offerings align well with this trend, tapping into a growing customer base interested in natural health solutions.
• Diverse Product Range: DXN offers a variety of products, including food supplements, personal care, and household products. This diversity allows the company to cater to different market segments, enhancing its market reach.
2. Strong Brand and Global Presence
• Established Reputation: DXN has built a strong brand reputation over the years, particularly in the direct selling model, which enhances customer trust and loyalty.
• International Expansion: DXN has expanded its operations to numerous countries worldwide, providing access to various markets. Its international presence allows it to capture diverse consumer needs and preferences, further enhancing growth potential.
3. Innovative Research and Development
• Focus on R&D: The company invests in research and development to improve existing products and develop new ones. This commitment to innovation can lead to a stronger product lineup that meets changing consumer demands.
• Health Benefits of Ganoderma: As a pioneer in promoting Ganoderma-based products, DXN can capitalize on the growing interest in herbal remedies and natural supplements. Research supporting the health benefits of Ganoderma can further enhance product credibility and consumer interest.
4. Strong Business Model
• Direct Selling Model: DXN operates through a direct selling model, which allows for lower overhead costs and the potential for high-profit margins. This model also incentivizes distributors, creating a motivated sales force that can drive growth.
• Global Network of Distributors: The company has a vast network of distributors, which can help accelerate market penetration and product awareness. A strong distributor network can facilitate quicker expansion and customer acquisition.
5. Emphasis on Education and Training
• Training Programs: DXN provides training and support to its distributors, equipping them with the knowledge and tools needed to effectively sell the products. This emphasis on education can lead to better sales performance and distributor retention.
• Health Awareness Initiatives: By promoting health education and awareness, DXN can position itself as a thought leader in the health and wellness space, attracting more customers and distributors to its network.
6. Adaptability to Market Changes
• Agility in Product Development: DXN has shown the ability to adapt its product offerings based on market trends and consumer preferences. This adaptability is crucial in a rapidly changing industry.
• Response to Consumer Needs: The company can respond quickly to emerging health trends, ensuring that its products remain relevant and appealing to consumers.
7. Sustainability Initiatives
• Focus on Natural Ingredients: As consumers become more conscious of sustainability and environmental impacts, DXN’s commitment to natural ingredients and sustainable practices can enhance its appeal in the market.
• Long-Term Viability: Companies that align with sustainability trends are often viewed favorably by consumers and investors, which can contribute to long-term growth potential.
Conclusion
DXN Holdings Bhd possesses numerous attributes that suggest unlimited potential for growth and expansion in the health and wellness sector. Its strong brand presence, diverse product offerings, commitment to innovation, effective business model, and adaptability to market changes position it well for future success. By leveraging these strengths and capitalizing on industry trends, DXN can continue to grow and expand its impact in the global market.
1 week ago
buy on short term knee jerk reaction. Easy money to make, 😜 2QFY25 results fell short
DXN’s 2QFY25 underperformed on weaker-than-expected sales. We expect 3Q-4QFY25E earnings to soften with expectation for sales volume in Peru and Bolivia (its top 2 sales contributors) to normalise after front-loading activities ahead of a scheduled price hike in Sep 2024. Our FY25E-FY27E earnings estimates are lowered by 2%-7%. The stock continues to trade at undemanding 12M PER of 8x post our earnings downgrades. Maintain BUY with a lower TP of MYR0.84 based on an unchanged 11x CY25E PER target
1 week ago
DXN - Notice of Book Closure
DXN HOLDINGS BHD.
Second Interim Dividend of 0.80 sen per ordinary share in respect of the financial year ending 28 February 2025
Kindly be advised of the following :
1) The above Company's securities will be traded and quoted "Ex - Dividend” as from: 12 Nov 2024
2) The last date of lodgment : 13 Nov 2024
3) Date Payable : 29 Nov 2024
Announcement Info
Company Name DXN HOLDINGS BHD.
Stock Name DXN
Date Announced 25 Oct 2024
Category Listing Circular
Reference Number ILC-25102024-00001
1 week ago
MEMORANDUM OF UNDERSTANDING DXN HOLDINGS BHD. ("DXNH" OR "THE COMPANY") UPDATE ON THE STATUS OF MEMORANDUM OF UNDERSTANDING
DXN HOLDINGS BHD.
Type Announcement
Subject MEMORANDUM OF UNDERSTANDING
Description DXN HOLDINGS BHD. ("DXNH" OR "THE COMPANY")
UPDATE ON THE STATUS OF MEMORANDUM OF UNDERSTANDING
Reference is made to the Company’s announcements made on 31 July 2023, 21 September 2023, 9 October 2023, 16 October 2023, 25 October 2023, 24 January 2024, 23 April 2024, 26 July 2024 and 8 August 2024 respectively. The Board of Directors of DXN HOLDINGS BHD. ("DXNH" OR "THE COMPANY") wishes to update the status of the following Memorandum of Understanding ("MOU"):-
1. MOU dated 30 July 2023 entered into between the Company and Universiti Tunku Abdul Rahman and Hospital Universiti Tunku Abdul Rahman and Yayasan Prihatin Nasional
- There has been no material development on the status of this MOU since the last announcement made on 26 July 2024.
2. Memorandum of Agreement dated 20 September 2023 entered into between the Company and Persatuan Holistik Dan Herba Malaysia
- There has been no material development on the status of this Memorandum of Agreement since the last announcement made on 26 July 2024.
3. MOU dated 8 October 2023 entered into between the Company and UOC Sdn. Bhd.
- There has been no material development on the status of this MOU since the last announcement made on 26 July 2024.
4. MOU dated 15 October 2023 entered into between the Company and European Wellness Centers Inc
- There has been no material development on the status of this MOU since the last announcement made on 26 July 2024.
5. MOU dated 27 May 2024 entered into between Dexin Morocco with the Ministry of Industry and Trade and the Ministry of Investment, Convergence and Evaluation of Public Policies
- There has been no material development on the status of this MOU since the last announcement made on 8 August 2024.
Further announcement on the status of the MOU will be made in due course in accordance with the Listing Requirements of Bursa Malaysia Securities Berhad.
This announcement is dated 24 October 2024.
1 week ago
Second Interim Dividend
DXN HOLDINGS BHD.
Entitlement subject Second Interim Dividend
Entitlement description Second Interim Dividend of 0.80 sen per ordinary share in respect of the financial year ending 28 February 2025
Ex-Date 12 Nov 2024
Entitlement date 13 Nov 2024
Entitlement time 5:00 PM
Financial Year End 28 Feb 2025
Period
Share transfer book & register of members will be to closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date 29 Nov 2024
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers 13 Nov 2024
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units)
(If applicable)
Entitlement indicator Currency
Announced Currency Malaysian Ringgit (MYR)
Disbursed Currency Malaysian Ringgit (MYR)
Entitlement in Currency Malaysian Ringgit (MYR) 0.0080
Par Value (if applicable)
Registrar or Service Provider name, address, telephone no BOARDROOM SHARE REGISTRARS SDN BHD
11th Floor, Menara Symphony
No. 5, Jalan Prof. Khoo Kay Kim (Jalan Semangat)
Seksyen 13
46200 Petaling Jaya
Selangor
Malaysia
Tel:0378904700
Fax:0378904670
1 week ago
DXN Holdings Bhd has several factors that could indicate potential for growth:
1. Rising Demand for Health and Wellness Products: There’s a growing global interest in health and wellness, especially in natural and plant-based products. DXN’s focus on Ganoderma, spirulina, and other health-focused items aligns well with this trend, which may fuel demand and revenue growth.
2. Extensive Distribution Network: DXN operates in over 180 countries through a multilevel marketing model. This broad network allows them to reach a global customer base and scale quickly in emerging markets without extensive infrastructure investment.
3. Expansion Potential in New Markets: DXN has the opportunity to expand further into regions with a growing middle class, such as Southeast Asia, Africa, and parts of Latin America. Increased disposable income and health awareness in these regions can drive demand for DXN’s offerings.
4. Diverse Product Range: DXN offers a wide array of products, including supplements, cosmetics, and food items. This diversification helps mitigate risk from market changes and allows the company to adapt to shifts in consumer preferences.
5. Focus on Research and Development: DXN has invested in R&D to improve and expand its product line, which can increase customer loyalty and create new revenue streams as consumers seek high-quality, science-backed wellness products.
6. Sustainable Practices and Vertical Integration: DXN controls its supply chain from cultivation to production, which can lower costs and ensure product quality. This control over sourcing and production also appeals to health-conscious consumers looking for sustainably-produced goods.
7. Strong Financial Position: If DXN continues to show profitability, this can attract investors looking for solid returns in the health and wellness sector. Financial health can also support strategic investments, further boosting the company’s competitive edge.
These factors combined suggest that DXN is well-positioned to capitalize on global wellness trends, expand its market share, and potentially provide stable returns to investors.
1 week ago
DXN Holdings Bhd 具有以下几方面的潜力，可能促成其未来增长：
1. 健康和保健产品需求增长：全球对健康和保健产品的兴趣不断增长，特别是对天然和植物基产品的需求。DXN 以灵芝、螺旋藻等健康产品为主，符合这一趋势，有望推动需求和收入增长。
2. 广泛的分销网络：DXN 通过多层次营销模式在180多个国家运营。这个广泛的网络使其能够接触到全球客户基础，并在新兴市场迅速扩展，而无需大量基础设施投资。
3. 新市场扩展潜力：DXN 有机会进一步扩展至中产阶级增长的地区，如东南亚、非洲和拉丁美洲的部分地区。随着这些地区的可支配收入增加和健康意识提高，可能会推动对DXN产品的需求。
4. 多样化的产品范围：DXN 提供包括补充剂、化妆品和食品在内的多种产品。多样化有助于减轻市场变化的风险，使公司能够适应消费者偏好的转变。
5. 专注于研发：DXN 投资于研发以改进和扩展其产品线，这可以增强客户忠诚度，并创造新的收入来源，以满足消费者对高质量、科学支持的健康产品的需求。
6. 可持续的实践与垂直整合：DXN 控制着从种植到生产的供应链，这不仅可以降低成本，还能确保产品质量。对可持续生产商品的关注也符合健康意识较高的消费者的需求。
7. 良好的财务状况：如果 DXN 能继续保持盈利，这将吸引希望在健康和保健领域获得稳定回报的投资者。良好的财务状况也可以支持战略投资，进一步提升公司竞争优势。
这些因素表明，DXN 在全球保健趋势中具有良好的发展前景，有机会扩大市场份额，并有可能为投资者提供稳定的回报。
1 week ago
DXN Holdings Bhd mempunyai beberapa faktor yang menunjukkan potensi untuk pertumbuhan masa depan:
1. Permintaan Meningkat terhadap Produk Kesihatan dan Kesejahteraan: Terdapat minat global yang semakin meningkat terhadap produk kesihatan dan kesejahteraan, terutamanya yang berasaskan bahan semula jadi dan tumbuhan. Fokus DXN pada Ganoderma, spirulina, dan produk kesihatan lain selari dengan trend ini, yang boleh meningkatkan permintaan dan pertumbuhan pendapatan.
2. Rangkaian Pengedaran yang Luas: DXN beroperasi di lebih 180 negara melalui model pemasaran berbilang aras (MLM). Rangkaian yang luas ini membolehkannya mencapai pelanggan di seluruh dunia dan berkembang pesat di pasaran baru tanpa memerlukan pelaburan besar dalam infrastruktur.
3. Potensi Pengembangan di Pasaran Baharu: DXN berpeluang untuk berkembang lebih jauh ke kawasan dengan peningkatan kelas pertengahan, seperti di Asia Tenggara, Afrika, dan beberapa bahagian di Amerika Latin. Peningkatan pendapatan boleh guna dan kesedaran kesihatan di kawasan ini dapat mendorong permintaan terhadap produk DXN.
4. Kepelbagaian Produk: DXN menawarkan pelbagai jenis produk termasuk suplemen, kosmetik, dan makanan. Kepelbagaian ini membantu mengurangkan risiko perubahan pasaran dan membolehkan syarikat menyesuaikan diri dengan perubahan dalam keutamaan pengguna.
5. Fokus kepada Penyelidikan dan Pembangunan: DXN melabur dalam R&D untuk meningkatkan dan memperluas rangkaian produknya, yang dapat meningkatkan kesetiaan pelanggan dan mencipta aliran pendapatan baharu apabila pengguna mencari produk kesihatan berkualiti tinggi yang berasaskan sains.
6. Amalan Lestari dan Integrasi Menegak: DXN mengawal rantaian bekalannya dari penanaman hingga pengeluaran, yang dapat menurunkan kos dan memastikan kualiti produk. Kawalan ini juga menarik minat pengguna yang mementingkan produk yang dihasilkan secara lestari.
7. Kedudukan Kewangan yang Kukuh: Jika DXN terus menunjukkan keuntungan, ini boleh menarik pelabur yang mencari pulangan stabil dalam sektor kesihatan dan kesejahteraan. Kesihatan kewangan juga dapat menyokong pelaburan strategik, seterusnya meningkatkan kelebihan daya saing syarikat.
Gabungan faktor-faktor ini menunjukkan bahawa DXN berada dalam posisi yang baik untuk memanfaatkan trend kesejahteraan global, memperluas penguasaan pasaran, dan berpotensi memberikan pulangan yang stabil kepada pelabur.
1 week ago
Next year, instead of paying out cash dividends, issue a share dividend. Many US companies pay out share dividends rather than cash dividends.
1 week ago
dxn share price looks no strength....could it be due to afraid of higher tax going to imposed by US if trump win...
1 week ago
BUY
Share Price MYR 0.59
12m Price Target MYR 0.84 (+47%)
Previous Price Target MYR 0.85
Company Description
DXN Holdings distributes consumer products globally
under a direct selling model
Statistics
52w high/low (MYR)
3m avg turnover (USDm)
Free float (%)
Issued shares (m)
Market capitalisation
Major shareholders:
LSJ Global Sdn Bhd
Gano Global
na
Price Performance
0.760
0.740
0.720
0.700
0.680
0.660
0.640
0.620
0.600
0.580
0.71/0.59
0.3
15.8
4,825
MYR2.8B
USD655M
68.0%
13.3%
1 week ago
Maintain BUY with a trimmed TP of MYR0.84
DXN’s 2QFY25 underperformed on weaker-than-expected sales. We expect
3Q-4QFY25E earnings to soften with expectation for sales volume in Peru
and Bolivia (its top 2 sales contributors) to normalise after front-loading
activities ahead of a scheduled price hike in Sep 2024. Our FY25E-FY27E
earnings estimates are lowered by 2%-7%. The stock continues to trade at
undemanding 12M PER of 8x post our earnings downgrades. Maintain BUY
with a lower TP of MYR0.84 based on an unchanged 11x CY25E PER target.
1HFY25 earnings reflected only 43% of FY25E
DXN’s 2QFY25 core net profit of MYR66m (-15% YoY, -23% QoQ) brought
1HFY25 core net profit to MYR152m (-9% YoY). The latter accounted for
just 43%/42% of our/consensus full-year earnings estimates. A second
interim of 0.8sen (1QFY25: 0.9sen, DPR: 52%) was declared, translating to
into a payout ratio of 60% (of headline net profit). The earnings miss was
largely due to weaker-than-expected sales.
Sales growth marred by higher operating costs
The group’s revenue grew +7% YoY on the back of higher sales volume in
its top 2 markets, Peru and Bolivia, given front-loading activities ahead of
a scheduled price adjustment in Sep 2024. Nonetheless, the topline growth
was still short of our earlier forecast of +21% for FY25E with the shortfall
coming from its other top 10 markets like India and Mexico. Pre-tax profit
however declined by -6% YoY on unfavourable USD/MYR FX movements,
and higher employee and freight shipping costs.
Lowered FY25E-FY27E earnings estimates by 2%-7%
Factoring in the weak set of results, our FY25E/FY26E/FY27E earnings
estimates are revised by -7%/-2%/-2%. We believe that DXN’s 3Q-4QFY25E
earnings might ease as (i) sales volume normalises post-price hikes in Peru
and Bolivia in 3QFY25, and (ii) MYR continues to strengthen against USD.
To mitigate this, we expect the group to ramp up member activities, and
new product launches in its top 10 markets to drive sales momentum.
FYE Feb (MYR m) FY23A FY24A FY25E FY26E FY
1 week ago
DXN - Notice of Book Closure
DXN - Notice of Book Closure
ILC-25102024-00001
Second Interim Dividend of 0.80 sen per ordinary share in respect of the
financial year ending 28 February 2025 Kindly be advised of the following :
1) The above Company's securities will be traded and quoted "Ex - Dividend? as
from: 12 Nov 2024 2) The last date of lodgment : 13 Nov 2024 3) Date Payable :
29 Nov 2024
MANAGER, REF. DATA MANAGEMENT
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com
25/10/2024 07:00 AM
Ref Code: 202410255100032
6 days ago
cun, net profit turun sedikit je... next Q melambung :)
Thursday, 24 Oct 2024
7:01PM
DXN MEMORANDUM OF UNDERSTANDING
6:53PM
DXN Second Interim Dividend
6:52PM
DXN 1H net profit 157.032 million (decreased 2.24%)
6 days ago
DXN Holdings Bhd’s share price being labeled as undervalued, particularly according to analysts from Maybank, can be attributed to several factors:
1. **Strong Financial Performance**: If DXN has consistently shown strong revenue growth, profitability, and a solid balance sheet, analysts might believe that the market has not fully recognized its financial strength, leading to an undervalued share price.
2. **Market Position**: As a leading player in the direct selling and wellness products sector, DXN’s strong market presence and brand recognition could indicate that its growth potential is greater than what the current share price reflects.
3. **Growth Prospects**: Analysts may foresee significant growth opportunities for DXN, such as expanding into new markets or launching new products. If the company is well-positioned to capitalize on these opportunities, its current valuation might seem low.
4. **Industry Trends**: The wellness and health supplement industry is experiencing growth due to increasing consumer awareness. If DXN is aligned with these trends but the market hasn’t adjusted its valuation accordingly, the shares could be seen as undervalued.
5. **Earnings Forecasts**: Positive earnings forecasts from Maybank or other analysts could suggest that the company is expected to outperform market expectations, which would justify a higher share price.
6. **Comparison with Peers**: If DXN’s valuation metrics (like price-to-earnings ratio) are lower than those of its competitors, analysts may conclude that it is undervalued compared to its peers, suggesting that the market hasn’t priced in its true worth.
7. **Market Sentiment**: Overall market sentiment can also play a role. If broader market conditions have led to negative sentiment around the sector, even strong companies like DXN may be sold off, resulting in a lower share price.
In summary, DXN Holdings Bhd's share price being considered undervalued by Maybank likely stems from a combination of its solid financial performance, growth prospects, industry trends, and comparisons with competitors.
6 days ago
Undervalued
😀
ROE 22.14
P/E 9.28
EPS 6.20
DPS 3.60
DY 6.26%
NTA 0.2800
P/B 2.05
RPS 37.80
PSR 1.52
Market Cap 2,866.4M
Shares (mil) 4,985.00
6 days ago
RSI(14) Oversold 24.1
Stochastic(14) Oversold 0.0
Average Volume (3M) 2,066,000
Relative Volume 0.4
6 days ago
LIST OF TOP 30 HOLDERS AS AT 31 MAY 2024
No. Name Holdings %
1 LSJ GLOBAL SDN BHD 3,090,465,105 62.148
2 GANO GLOBAL SUPPLEMENTS PTE. LTD. 661,859,895 13.310
3 AFFIN HWANG NOMINEES (TEMPATAN) SDN. BHD.
PLEDGED SECURITIES ACCO UNT FOR LSJ GLOBAL SDN. BHD. 170,000,000 3.419
4 LSJ GLOBAL SDN. BHD. 134,315,700 2.701
5 PHILLIP NOMINEES (TEMPATAN) SDN BHD
PLEDGED SECURITIES ACCOUNT FOR LIM CHEA LIN 76,632,900 1.541
6 AMSEC NOMINEES (TEMPATAN) SDN BHD
AMBANK (M) BERHAD 72,100,000 1.450
7 AZAAL TRADING SDN BHD 45,703,500 0.919
8 CITIGROUP NOMINEES (ASING) SDN BHD
CBNY FOR NORGES BANK (FI 17) 30,088,100 0.605
9 DB (MALAYSIA) NOMINEE (TEMPATAN) SENDIRIAN BERHAD
DEUTSCHE TRUSTEES MALAYSIA BERHAD FOR EASTSPRING INVESTMENTSSMALL-CAP FUND 24,161,400 0.486
10 CITIGROUP NOMINEES (TEMPATAN) SDN BHD
EMPLOYEES PROVIDENT FUND BOARD (PHEIM) 20,384,500 0.410
11 LIM CHEA LIN 20,101,800 0.404
12 CITIGROUP NOMINEES (ASING) SDN BHD
EXEMPT AN FOR CITIBANK NEW YORK (NORGES BANK 14) 18,635,300 0.375
13 CITIGROUP NOMINEES (TEMPATAN) SDN BHD
KUMPULAN WANG PERSARAAN (DIPERBADANKAN) (KENANGA) 15,266,800 0.307
14 CARTABAN NOMINEES (TEMPATAN) SDN BHD
PAMB FOR PRULINK EQUITY FOCUS FUND 14,557,200 0.293
15 CITIGROUP NOMINEES (TEMPATAN) SDN BHD
URUSHARTA JAMAAH SDN. BHD. (AHAM AM 2) 11,866,400 0.239
16 CIMB ISLAMIC NOMINEES (TEMPATAN) SDN BHD
CIMB ISLAMIC TRUSTEE BERHAD - KENANGA SYARIAH GROWTH FUND 11,703,200 0.235
17 MAYBANK NOMINEES (TEMPATAN) SDN BHD
MAYBANK TRUSTEES BERHAD FOR DANA MAKMUR PHEIM (211901) 11,361,600 0.228
18 NAI JOO CHYI 11,000,000 0.221
19 NG SEM GUAN 10,615,000 0.213
20 MAYBANK SECURITIES NOMINEES (ASING) SDN BHD
PLEDGED SECURITIES ACCOUNT FOR MATHEW PURACKAL KUNCHERIA 10,413,000 0.209
21 CIMSEC NOMINEES (TEMPATAN) SDN BHD
CIMB FOR KAWAN FOOD MANUFACTURING SDN BHD (PB) 10,000,000 0.201
22 DB (MALAYSIA) NOMINEE (TEMPATAN) SENDIRIAN BERHAD
DEUTSCHE TRUSTEES MALAYSIA BERHAD FOR EASTSPRING INVESTMENTSMY FOCUS
FUND 9,922,300 0.200
23 HSBC NOMINEES (TEMPATAN) SDN BHD
HSBC (M) TRUSTEE BHD FOR PERTUBUHAN KESELAMATAN SOSIAL (UOB
AMM6939-406) 9,437,200 0.190
24 PHILLIP NOMINEES (TEMPATAN) SDN BHD
EXEMPT AN FOR PHILLIP CAPITAL MANAGEMENT SDN BHD 9,211,400 0.185
25 MAYBANK NOMINEES (TEMPATAN) SDN BHD
MTRUSTEE BHD FOR AIIMAN TNB RBTF (EQ) (433139) 8,774,800 0.176
26 CIMB GROUP NOMINEES (TEMPATAN) SDN BHD
CIMB BANK BERHAD (EDP 2) 7,909,400 0.159
27 TEH CHAI PENG 7,648,200 0.154
28 MAYBANK NOMINEES (TEMPATAN) SDN BHD
NATIONAL TRUST FUND (IFM UOBAM) (446560) 7,571,700 0.152
29 CITIGROUP NOMINEES (TEMPATAN) SDN BHD
KUMPULAN WANG PERSARAAN (DIPERBADANKAN) (ESPRING ABSR EQ) 6,848,500 0.138
30 HLB NOMINEES (TEMPATAN) SDN BHD
PLEDGED SECURITIES ACCOUNT FOR SIVA KUMAR A/L M JEYAPALAN 6,128,500 0.123
Total: 4,544,683,400 91.392
6 days ago
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-05 10:00:00
EMA 5
Hourly
BUY
2024-11-05 09:05:00
EMA 5
5 Mins
BUY
2024-11-05 09:00:00
EMA 5
10 Mins
BUY
2024-11-05 09:00:00
ADX
5 Mins
BUY
Apps
Top Articles
1
3
Stockhistory
5
6
7
BFM Podcast
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
gsooi100
Haha… good question. Maybe coming AGM can ask boss…
2024-07-29 10:39